医薬品原薬の世界市場（2021年～2028年）

当レポートでは、世界の医薬品原薬市場について調査分析し、市場力学、業界分析、市場分析、競合情勢など、体系的な情報を提供しています。

目次

第1章 世界の医薬品原薬市場の調査手法と範囲

• 調査手法
• 調査の目的と調査範囲

第2章 世界の医薬品原薬市場－市場の定義と概要

第3章 世界の医薬品原薬市場－エグゼクティブサマリー

• 市場の内訳：タイプ別
• 市場の内訳：アプリケーション別
• 市場の内訳：性質別
• 市場の内訳：製造タイプ別
• 市場の内訳：地域別

第4章 世界の医薬品原薬市場－市場力学

• 市場に影響を与える要因
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 世界の医薬品原薬市場－業界分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 規制分析

第6章 世界の医薬品原薬市場－COVID-19分析

• 市場でのCOVID-19の分析
  • COVID-19以前の市場シナリオ
  • 現在のCOVID-19の市場シナリオ
  • COVID-19以後の市場シナリオ/将来の市場シナリオ
• COVID-19における価格の力学
• 需要と供給のスペクトル
• パンデミック時の市場に関連する政府のイニシアチブ
• メーカーの戦略的イニシアチブ
• 結論

第7章 世界の医薬品原薬市場：タイプ別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）：タイプ別
  • 市場魅力指数：タイプ別
• 合成API*
  • イントロダクション
  • 市場規模分析（100万米ドル）（2019年～2028年）、および前年比成長分析（％）（2020年～2028年）
• バイオテクノロジーAPI

第8章 世界の医薬品原薬市場：アプリケーション別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）：アプリケーション別
  • 市場魅力指数：アプリケーション別
• 心血管*
  • イントロダクション
  • 市場規模分析（100万米ドル）（2019年～2028年）、および前年比成長分析（％）（2020年～2028年）
• 糖尿病
• 腫瘍学
• 整形外科
• 神経学
• NSAIDS
• その他

第9章 世界の医薬品原薬市場：性質別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）：性質別
  • 市場魅力指数：性質別
• ジェネリックAPI*
  • イントロダクション
  • 市場規模分析（100万米ドル）（2019年～2028年）、および前年比成長分析（％）（2020年～2028年）
• イノベーターAPI

第10章 世界の医薬品原薬市場：製造タイプ別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）：製造タイプ別
  • 市場魅力指数：製造タイプ別
• キャプティブ*
  • イントロダクション
  • 市場規模分析（100万米ドル）（2019年～2028年）、および前年比成長分析（％）（2020年～2028年）
• マーチャント

第11章 世界の医薬品原薬市場：地域別

• イントロダクション
  • 市場規模分析（100万米ドル）（2019年～2028年）、および前年比成長分析（％）（2020年～2028年）：地域別
  • 市場魅力指数：地域別
• 北米
• 欧州
• 南米
• アジア太平洋
• 中東とアフリカ

第12章 世界の医薬品原薬市場－競合情勢

• 主な発展と戦略
• 企業シェア分析
• 製品のベンチマーク

第13章 世界の医薬品原薬市場－企業プロファイル概要

• Aurobindo Pharma*
  • 企業概要
  • 製品ポートフォリオおよび説明
  • 主要ハイライト
  • 財務概要
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc.
• Novartis AG
• BASF SE
• Boehringer Ingelheim GmbH
• Dr. Reddy's Laboratories Ltd
• Lupin Ltd
• Mylan NV
• Sun Pharmaceutical Industries Ltd

第14章 世界の医薬品原薬市場－DataM

• 付録
• 当社・サービスについて
• お問い合わせ

Market Overview

The global active pharmaceutical ingredient market size was valued at US$ XX million in 2019 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX% during the forecast period (2021-2028).

Active pharmaceutical ingredient (API) is a part of any drug that produces its effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. They are produced using highly technological industrial processes, both during the R&D and the commercial production phase.

Market Dynamics

The global active pharmaceutical ingredient market growth is driven by an increase in the number of chronic diseases, an increase in the number of geriatric populations around the world. The increased utilization of biopharmaceuticals and rising investments in research and development for drug manufacturing are all contributing to the growth of the global active pharmaceutical ingredients (API) market.

The surge in the use of biosimilar products will drive the market growth

Biosimilars are generic versions of copyrighted biologic medications that do not meet the same severe regulatory criteria as branded biologic medicines. Thus, the patents and other intellectual property rights for originator biologics are likely to expire, allowing biosimilars to join the market. As a result, the surge in the use of biosimilar products is propelling the growth of the active pharmaceutical ingredients (API) market during the forecast period.

Moreover, the launches of new drugs and biological products, acquisitions, collaborations, and regional expansions are some of the strategic initiatives to maintain stability in the market. This is likely to fuel market growth in the near future. For instance, in 2020, Quartic.ai and Bright Path Labs collaborated to develop AI-based technology for the continuous manufacturing of critical AP The active pharmaceutical ingredients (API) market has traditionally been dominated by drugs, such as anti-infectives and diabetes, cardiovascular, analgesics, and pain management drugs. However, as per the R&D trends, the demand is shifting toward the development of complex APIs used in novel formulations, targeting niche therapeutic areas. Is that are required for producing crucial small-molecule drugs.

Another important growth driver is the rise in the geriatric population around the world. According to the United Nations, there were 703 million people aged 65 and above worldwide in 2019. Such a high geriatric population gives way to contract a lot of chronic and acute diseases which would require newer drugs to mitigate their effects, thus leading to a rise in market growth.

High manufacturing costs will hamper the market growth

The high manufacturing cost of APIs is one of the major challenges faced by market players. Manufacturers often have to make costly investments for improvements in their manufacturing facilities to ensure compliance with standards such as the cGMP. This includes the renovation of production facilities, inculcating familiarity with qualification requirements and processes, and building a dossier of product efficacy and safety tests that meet the requirements of regulatory authorities. Furthermore, the costs of obtaining regulatory approvals are relatively higher for firms with small volumes. The chemical synthesis of APIs also often requires expensive and uncommon building blocks and raw materials, which further adds to API manufacturing costs. These factors are hampering the growth of the market in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic had a favorable impact on the market as the countries and major players are manufacturing huge amounts of ingredients to maintain the demand for the treatment of COVID 19. The outbreak of COVID-19 has led drug manufacturers to redirect their models to focus on a larger pool of patients. For instance, the United States requested that hydroxychloroquine (HCQ) be imported from India as a treatment for coronavirus. The virus has also disrupted the drug supply chain in Canada and may cause problems for patients in the country. Canadian pharma majors expand their programs with countries other than China to gain access to new regions. On March 24, 2020, the WHO announced that it had initiated a global mega trial of the four most promising drugs against COVID-19. Countries are in a global race to develop and mass-produce an efficient vaccine to fight COVID-19. The economic and social burden of pandemics has prompted government bodies to increase funding for vaccine development on a global scale. These factors will drive the growth of the market during a pandemic.

Segment Analysis

The cardiovascular segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

The cardiovascular segment holds a significant share due to the vast population using various CVD drugs owing to the high prevalence of cardiovascular diseases. According to the European Society of Cardiology 2019 Statistics, cardiovascular diseases (CVD) remain the leading cause of mortality and a major cause of morbidity in Europe. Currently, there are more than 6 million new cases of CVD in the EU and more than 11 million in Europe as a whole, every year. With almost 49 million people living with the disease in the EU, the cost to the EU economies is high at EUR 210 billion a year. This factor will drive the growth of the segment in the forecast period.

Geographical Analysis

North America region holds the largest market share of the global active pharmaceutical ingredient market

North America currently dominates the market for active pharmaceutical ingredients and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increasing incidences of disease and rising aging population. The United States holds the majority of the market in the North American region.

The recent political and trade policies implemented by the US government to increase import duties and taxes are expected to drive operational costs and increase the pricing pressure on the manufacturers. The FDA has also increased the application fees for new drug approvals and has increased the number of periodic inspections conducted on various off-shore contract manufacturing facilities to ensure the supply of high-quality products to the US market. These factors are driving the growth of the market in the region.

Competitive Landscape

The active pharmaceutical ingredient market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Novartis AG, BASF SE, Boehringer Ingelheim GmbH, Dr. Reddy's Laboratories Ltd, Lupin Ltd, Mylan NV, Sun Pharmaceutical Industries Ltd among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the active pharmaceutical ingredient market globally. For instance, in April 2020, Boehringer Ingelheim acquired Northern Biologics. This acquisition broadened Boehringer Ingelheim's oncology product portfolio.

Novartis AG

Overview: Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars, and ophthalmic products.

Product Portfolio:

Anti-Infectives: The Sandoz Anti-Infectives & API business is a fully-integrated provider of affordable, high-quality pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms.

Why Purchase the Report?

Visualize the composition of the global active pharmaceutical ingredient market segmentation by type, application, nature, manufacturing type, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global active pharmaceutical ingredient market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global active pharmaceutical ingredient market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global active pharmaceutical ingredient market report would provide an access to an approximately 40+ market data table, 45+ figures, and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Active Pharmaceutical Ingredient Market- By Type

Synthetic API

Biotech API

Global Active Pharmaceutical Ingredient Market- By Application

Cardiovascular

Diabetes

Oncology

Orthopaedics

Neurology

NSAIDS

Others

Global Active Pharmaceutical Ingredient Market- By Nature

Generic API

Innovator API

Global Active Pharmaceutical Ingredient Market- By Manufacturing type

Captive

Merchant

Global Active Pharmaceutical Ingredient Market- By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America

Table of Contents

1. Global Active Pharmaceutical Ingredient Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Global Active Pharmaceutical Ingredient Market- Market Definition and Overview

3. Global Active Pharmaceutical Ingredient Market- Executive Summary

• 3.1. Market Snippet by Type
• 3.2. Market snippet by Application
• 3.3. Market snippet by Nature
• 3.4. Market Snippet by Manufacturing type
• 3.5. Market Snippet by Region

4. Global Active Pharmaceutical Ingredient Market-Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Infectious, Genetic, Cardiovascular, and Other Chronic Disorders
    • 4.1.1.2. Increasing Adoption of Biologicals and Biosimilars
  • 4.1.2. Restraints:
    • 4.1.2.1. Drug Price Control Policies Across Various Countries
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Global Active Pharmaceutical Ingredient Market- Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis

6. Global Active Pharmaceutical Ingredient Market- COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Global Active Pharmaceutical Ingredient Market- By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
  • 7.1.2. Market Attractiveness Index, By Type Segment
• 7.2. Synthetic API*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
• 7.3. Biotech API

8. Global Active Pharmaceutical Ingredient Market- By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Cardiovascular*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
• 8.3. Diabetes
• 8.4. Oncology
• 8.5. Orthopaedics
• 8.6. Neurology
• 8.7. NSAIDS
• 8.8. Others

9. Global Active Pharmaceutical Ingredient Market- By Nature

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Nature
  • 9.1.2. Market Attractiveness Index, By Nature Segment
• 9.2. Generic API*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
• 9.3. Innovator API

10. Global Active Pharmaceutical Ingredient Market- By Manufacturing type

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Manufacturing type
  • 10.1.2. Market Attractiveness Index, By Manufacturing type Segment
• 10.2. Captive*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
• 10.3. Merchant

11. Global Active Pharmaceutical Ingredient Market- By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Nature
  • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Manufacturing type
  • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Nature
  • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Manufacturing type
  • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Nature
  • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Manufacturing type
  • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Nature
  • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Manufacturing type
  • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Nature
  • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Manufacturing type

12. Global Active Pharmaceutical Ingredient Market- Competitive Landscape

• 12.1. Key Developments and Strategies
• 12.2. Company Share Analysis
• 12.3. Product Benchmarking

13. Global Active Pharmaceutical Ingredient Market- Company Profiles

• 13.1. Aurobindo Pharma*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Key Highlights
  • 13.1.4. Financial Overview
• 13.2. Teva Pharmaceutical Industries Ltd
• 13.3. Pfizer Inc.
• 13.4. Novartis AG
• 13.5. BASF SE
• 13.6. Boehringer Ingelheim GmbH
• 13.7. Dr. Reddy's Laboratories Ltd
• 13.8. Lupin Ltd
• 13.9. Mylan NV
• 13.10. Sun Pharmaceutical Industries Ltd

LIST NOT EXHAUSTIVE

14. Global Active Pharmaceutical Ingredient Market- DataM

• 14.1. Appendix
• 14.2. About Us and Services
• 14.3. Contact Us